Exploiting tumour hypoxia in cancer treatment
Top Cited Papers
- 1 June 2004
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 4 (6), 437-447
- https://doi.org/10.1038/nrc1367
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Hypoxia-mediated tumour targetingGene Therapy, 2003
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- Gene transfer of antisense hypoxia inducible factor-1 α enhances the therapeutic efficacy of cancer immunotherapyGene Therapy, 2001
- A Novel Class of Antitumor Prodrug, 1-(2′-Oxopropyl)-5-fluorouracil (OFU001), That Releases 5-Fluorouracil upon Hypoxic IrradiationJapanese Journal of Cancer Research, 2000
- Hypoxia-specific cytotoxins in cancer therapySeminars in Radiation Oncology, 1996
- Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumoursNature, 1996
- Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954European Journal of Cancer, 1995
- Clinical trials of radiosensitizers: What should we expect?International Journal of Radiation Oncology*Biology*Physics, 1984
- Clostridial oncolysis in manEuropean Journal of Cancer (1965), 1967